Report and termination of the liquidity contract with Gilbert Dupont
Investor & Analyst Update, New York, May 16th, 2016
First quarter 2016 report
Upcoming investor conferences
Innate Pharma to hold its Annual General Meeting of shareholders on June 2, 2016 and the release of its reference document (in french)
First-in-class CD39 checkpoint inhibitor presented at the AACR meeting
New data presented at AACR support the rationale for combination treatment with monalizumab and durvalumab
Innate Pharma presents new CD73 checkpoint inhibitor program
New preclinical data further supporting the development of IPH4301 presented at the AACR meeting
AACR 2016: Innate Pharma displays broad innovative pipeline in immuno-oncology
